A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy

Front Immunol. 2024 Dec 3:15:1485109. doi: 10.3389/fimmu.2024.1485109. eCollection 2024.

Abstract

Introduction: Bladder cancer was recognized as one of the most common malignant tumors in the urinary system, and treatment options remained largely limited to conventional surgery, radiotherapy, and chemotherapy, which limited patient benefits.

Methods: Researchers constructed an RNA transcriptome map of bladder cancer by integrating single-cell RNA sequencing and clinical data, identifying potential molecular targets for diagnosis and treatment. We also verified the antitumor activity of the target through in vitro experiment.

Results: A distinct tumor cell subpopulation characterized by elevated S100A8 expression exhibited high copy number variation, high stemness, and low differentiation. It interacted with myeloid cells via the MIF-(CD74+CD44) and MIF-(CD74+CXCR4) signaling pathways. This study underscored KDELR2's role in promoting cell proliferation, invasion, and migration, providing new therapeutic insights. Prognostic analysis revealed that KDELR2 correlated with poor survival, higher immune scores, and increased macrophage infiltration.

Discussion: The findings suggested that patients with high KDELR2 expression might benefit from immune checkpoint therapy. KDELR2 was also shown to enhance bladder cancer cell proliferation, invasion, and migration, highlighting it as a promising target for macrophage-focused drug development.

Keywords: KDELR2; S100A8; TCs; bladder cancer; macrophage.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Immunotherapy* / methods
  • Macrophages* / immunology
  • Macrophages* / metabolism
  • Signal Transduction / drug effects
  • Tumor-Associated Macrophages / drug effects
  • Tumor-Associated Macrophages / immunology
  • Tumor-Associated Macrophages / metabolism
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / genetics
  • Urinary Bladder Neoplasms* / immunology
  • Urinary Bladder Neoplasms* / therapy

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.